Alpenglow Biosciences Secures $24M+ in ARPA-H and NIH Contracts to Revolutionize Cancer and Prostate Diagnostics
We’re excited to announce that we’ve recently been awarded up to a combined $24M in contracts from the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes of Health (NIH) and secured additional investment to further our clinical product development!
Please review the full press release: Business wire
ARPA-H Precision Surgical Interventions contract
ARPA-H has awarded Jonathan T.C. Liu, Ph.D., University of Washington Professor and Scientific Co-Founder of Alpenglow Biosciences, a groundbreaking contract to develop a platform technology for precision tumor removal. The five-year ARPA-H contract (up to $21M) is part of the Cancer Moonshot initiative spearheaded by the Biden administration. Alpenglow, alongside elite academic medical centers, is set to transform the fight against cancer with its innovative AI-driven 3D Spatial Biology platform.
NIH SBIR Phase II contract
The NIH has awarded Alpenglow a $2M Phase II Small Business Innovation Research (SBIR) contract to further our development of prostate cancer diagnostics in collaboration with CorePlus, a leading digital pathology laboratory based in Puerto Rico. As part of the contract, Alpenglow will develop 3D pathology AI tests using prostate core biopsies.
Investing in the Alpenglow Aurora™ difference
On top of these contracts, Alpenglow received $1M in additional investment led by Dynamk Capital and Paul McEwan to develop further our Aurora™ platform for tissue-to-insights solutions leveraging 3D spatial biology.
Dr. Nicholas Reder, CEO and Co-Founder, said, “The Alpenglow Aurora™ platform is a paradigm shift. Its rapid imaging and AI-driven analysis are poised to redefine predictive diagnostics and intraoperative care, cementing our position at the vanguard of disruptive technology in pathology.”
Steve Pemberton, Senior Vice President of Commercial Development, added, “We're taking pathology from the microscope slide to the digital age. Our platform’s 3D, digital, and AI-enhanced capabilities will usher in a new era in clinical assessment of tissue.”
